Company Maker?, page-7

Oh @vrs37. Always such a Debbie Downer.

"How do you know it’s going to be positive impressive data in NOXCOVID ? Let’s see it, and see how it’s spun"
Of course we don't have full data in front of us. If we DID have full data, and the effect WAS impressive, the share price would be up and we would have missed out on making money and there would be nothing to discuss here. (I'm here to make money; not entirely sure why you're here!)

So to spell it out for you, let's review the evidence for getting some "positive impressive data" next week:
1. Comprehensive and independent preclinical data (from Hudson and ANU; solid collaborators)
2. PCT patent applications filed
3. NOXCOVID trial advanced to part 2. (A reminder, part 1 was dose escalation. Part 2 is dose-expansion "at the dose determined to be the optimal" from part 1).
4. A commitment to release clinical data within weeks
5. Using the phrase "in the clinic" in the announcement.

If you put all that evidence together you might get a very big clue about the contents of the next announcement. Opportunities like this don't come along very often.

(In my opinion only, do your own research, etc etc)